Victory Capital Management Inc. Has $1.01 Million Stake in Orthofix Medical Inc. (NASDAQ:OFIX)

Victory Capital Management Inc. grew its position in Orthofix Medical Inc. (NASDAQ:OFIX) by 3.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 64,807 shares of the medical device company’s stock after purchasing an additional 2,074 shares during the quarter. Victory Capital Management Inc.’s holdings in Orthofix Medical were worth $1,012,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Orthofix Medical in the second quarter valued at approximately $27,000. Quest Partners LLC acquired a new position in shares of Orthofix Medical in the second quarter valued at approximately $64,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Orthofix Medical by 25.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,435 shares of the medical device company’s stock valued at $125,000 after buying an additional 1,919 shares during the period. Arizona State Retirement System bought a new stake in shares of Orthofix Medical in the second quarter valued at approximately $139,000. Finally, XTX Topco Ltd bought a new stake in shares of Orthofix Medical in the second quarter valued at approximately $175,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Stock Down 1.1 %

NASDAQ OFIX opened at $19.13 on Thursday. The business has a fifty day moving average price of $16.74 and a two-hundred day moving average price of $15.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. Orthofix Medical Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $20.73. The stock has a market capitalization of $730.96 million, a PE ratio of -6.18 and a beta of 1.05.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Roth Mkm reiterated a “buy” rating and issued a $22.00 price target (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Stifel Nicolaus upgraded Orthofix Medical from a “hold” rating to a “buy” rating and boosted their price target for the company from $18.00 to $24.00 in a research note on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.